Literature DB >> 30472971

Reward systems and cognitions in Major Depressive Disorder.

Marie-Laure Cléry-Melin1, Fabrice Jollant1, Philip Gorwood1.   

Abstract

A lack of motivation and anhedonia represent frequent and pervasive symptoms in depression, although with poor specificity. Historically described as a response bias, reward-related impairments in depression may account for the important aspects of the cognitive impairments associated with diagnosis of major depressive disorder. Reward processing is a broad psychological construct that can be parsed into 3 distinct components known as "reinforcement learning" (learning), "reward responsiveness" (liking), and "motivation to obtain a reward" (wanting). Depressed patients respond hyposensitively to reward and maladaptively to punishment: this pattern is related to a dysfunction in the frontostriatal systems modulated by the monoamine systems; seems to be observed in medicated and unmedicated patients with depression and in healthy individuals with high levels of anhedonia; and could be observed in patients with a history of depression, even when in full remission. Considered to be cognitive impairments, reward-related-impairments may also constitute part of an underlying neurobiological vulnerability to major depressive disorder (MDD). For example, the reward-related impairment is state dependent and, more or less, correlated with symptom severity in some studies but has also been proposed as being trait like, with endophenotype characteristics, possibly contributing to the persistence of the disease or treatment resistance. The 3 core aspects of reward processing have specific neurobiological correlates that involve the ventral and dorsal striatum, lateral habenula, ventral tegmental area, orbitofrontal cortex, anterior cingulate cortex, and ventromedial and dorsolateral prefrontal cortex. These structures underline the important role of the dopaminergic mesolimbic pathway, but glutamate and serotonin could also have an important role, at least in some aspects of reward-related impairments.

Entities:  

Keywords:  anhedonia; cognition; dopamine; endophenotype; liking; motivation; neurotoxicity; reward; striatum; wanting

Mesh:

Year:  2018        PMID: 30472971     DOI: 10.1017/S1092852918001335

Source DB:  PubMed          Journal:  CNS Spectr        ISSN: 1092-8529            Impact factor:   3.790


  5 in total

1.  Neurocognitive predictors of self-reported reward responsivity and approach motivation in depression: A data-driven approach.

Authors:  Kean J Hsu; Mary E McNamara; Jason Shumake; Rochelle A Stewart; Jocelyn Labrada; Alexandra Alario; Guadalupe D S Gonzalez; David M Schnyer; Christopher G Beevers
Journal:  Depress Anxiety       Date:  2020-06-24       Impact factor: 6.505

2.  Prefrontal cortex eQTLs/mQTLs enriched in genetic variants associated with alcohol use disorder and other diseases.

Authors:  Honghuang Lin; Fan Wang; Andrew J Rosato; Lindsay A Farrer; David C Henderson; Huiping Zhang
Journal:  Epigenomics       Date:  2020-06-04       Impact factor: 4.778

3.  Personalized Psychiatry and Depression: The Role of Sociodemographic and Clinical Variables.

Authors:  Giampaolo Perna; Alessandra Alciati; Silvia Daccò; Massimiliano Grassi; Daniela Caldirola
Journal:  Psychiatry Investig       Date:  2020-03-12       Impact factor: 2.505

4.  Therapeutic Potential of Vortioxetine for Anhedonia-Like Symptoms in Depression: A Post Hoc Analysis of Data from a Clinical Trial Conducted in Japan.

Authors:  Koichiro Watanabe; Shinji Fujimoto; Tatsuro Marumoto; Tadayuki Kitagawa; Kazuyuki Ishida; Tadashi Nakajima; Yoshiya Moriguchi; Keita Fujikawa; Takeshi Inoue
Journal:  Neuropsychiatr Dis Treat       Date:  2022-02-19       Impact factor: 2.570

5.  Understanding the neurobiological basis of anhedonia in major depressive disorder - evidence for reduced neural activation during reward and loss processing.

Authors:  Udo Dannlowski; Nils Opel; Lavinia A Steinmann; Katharina Dohm; Janik Goltermann; Maike Richter; Verena Enneking; Marcia Lippitz; Jonathan Repple; Marco Mauritz
Journal:  J Psychiatry Neurosci       Date:  2022-08-10       Impact factor: 5.699

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.